Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neuroendocrine Tumors 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Kidney Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 44Paclitaxel 42Cisplatin 20Topotecan 17Gemcitabine 16Docetaxel 13Bevacizumab 13liposomal doxorubicin 7olaparib 6Cyclophosphamide 6pembrolizumab 5Surgical Procedures, Operative 5Filgrastim 5Etoposide 5Drug Therapy 5Amifostine 5sargramostim 4oregovomab 4catumaxomab 4anlotinib 4Imatinib Mesylate 4Hyperthermic Intraperitoneal Chemotherapy 4rucaparib 3pegfilgrastim 3niraparib 3ixabepilone 3aldesleukin 3Standard of Care 3Peripheral Blood Stem Cell Transplantation 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Ovarian Epithelial × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × Clear all
NCT00081276 2013-01-24

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
48 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡